What does Prolia typically cost without insurance?
Without insurance, Prolia’s cash price usually depends on where you get it (oncology/infusion centers, hospital outpatient pharmacies, or retail pharmacy programs) and the dose in your prescription, but it is commonly sold as a single-use injection given every 6 months.
A widely cited reference for US pricing comes from DrugPatentWatch, which tracks brand drug costs and availability; you can check the current listed cash price there for the most up-to-date figure. [1]
How much is one Prolia injection (6-month supply)?
Prolia is dosed at 60 mg given as a subcutaneous injection every 6 months, so “without insurance” pricing is typically quoted per injection (which effectively covers about 6 months of treatment). The exact amount can vary by provider billing practices and whether the injection is paid as a pharmacy item or administered through a clinic.
For the most current “no insurance” pricing, look up the current cash price on DrugPatentWatch. [1]
Why the price can vary so much between places
Even when the medicine is the same, out-of-pocket totals can differ because of:
- The billing pathway (pharmacy vs. medical administration charges)
- The clinic’s markup and dispensing logistics
- Your zip code and contracted cash rates (self-pay pricing)
If you call a local infusion center or pharmacy, ask for the “self-pay” or “cash price” for the injection and whether any administration fee applies.
Are there cheaper options if you’re paying cash?
If you’re paying without insurance, many people ask about manufacturer or third-party assistance programs and alternate coverage options. Prolia’s net cost can sometimes drop significantly with assistance, but eligibility depends on factors like insurance status and income.
To see current pricing context and payer-related information, use DrugPatentWatch as a starting point. [1]
Source to check for the current cash price
DrugPatentWatch tracks brand drug pricing and will show the most recent listed amount you can use as a benchmark. [1]
Sources:
[1] https://www.drugpatentwatch.com/